Bristol-Myers Hepatitis C Therapy Blunts Disease in Study
This article is for subscribers only.
Bristol-Myers Squibb Co., the New York drugmaker that has gained 25 percent in the past year, said its combination of three experimental medicines for hepatitis C successfully cleared the virus in 15 of 16 patients.
The results of the 24-week trial were released today before the start of the European Association for the Study of the Liver’s annual meeting in Amsterdam. The company plans to pick a dose for the treatment and move it into final-stage trials later this year.